

Appendix 4 (as supplied by the authors): Full Base Case Cost-Effectiveness Results

Genotype 1 Treatment-Naive Non-cirrhotic						
Treatment	Total Cost	Total QALYs	Versus PR Alone			Sequential ICUR
			Incremental Cost	Incremental QALYs	ICUR	
(0) no treatment	\$104,904	9.734	-	-	-	-
(1) PR48	\$114,132	10.839	-	-	-	\$8,353
(14) PAR/RIT12 + OMB12 + DAS12	\$143,379	11.835	\$29,247	0.996	\$29,354	\$48,060
(6) SOF12 + LDV12	\$152,762	11.857	\$38,631	1.018	\$37,951	\$435,528
Dominated or Extendedly Dominated Treatments						
(46) B24 PR28-48 RGT	\$135,218	11.370	\$21,086	0.531	\$39,710	ext. dominated
(42) S112 PR24-48 RGT	\$136,770	11.449	\$22,638	0.610	\$37,106	ext. dominated
(32) T12 PR24-48 RGT q8	\$137,381	11.400	\$23,250	0.561	\$41,452	dominated
(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	\$146,021	11.841	\$31,890	1.002	\$31,823	ext. dominated
(40) So12 PR12	\$146,140	11.651	\$32,008	0.812	\$39,431	dominated
(41) So12 PR24-48 RGT	\$150,969	11.589	\$36,837	0.750	\$49,113	dominated
(19) DAC12 + SOF12	\$176,431	11.800	\$62,300	0.961	\$64,831	dominated
(5) SIM12 + SOF12	\$178,356	11.700	\$64,224	0.861	\$74,582	dominated
(72) SOF12+ SIM12+RBV12	\$182,383	11.655	\$68,251	0.816	\$83,618	dominated
(4) SOF24 + RBV24	\$201,979	11.497	\$87,847	0.658	\$133,509	dominated
Genotype 1 Treatment-Naive Cirrhotic						
Treatment	Total Cost	Total QALYs	Versus PR Alone			Sequential ICUR
			Incremental Cost	Incremental QALYs	ICUR	
no treatment	\$101,355	7.043	-	-	-	-
PR48	\$120,140	8.659	-	-	-	\$11,628
SOF12 + LDV12	\$169,483	10.538	\$49,344	1.879	\$26,261	\$26,261
Dominated or Extendedly Dominated Treatments						
SIM12 PR24-48 RGT	\$149,012	9.557	\$28,872	0.899	\$32,123	ext. dominated
T12 PR24-48 RGT q8	\$153,580	9.219	\$33,441	0.561	\$59,622	dominated
B24 PR28-48 RGT	\$160,651	8.189	\$40,512	-0.470	dominated	dominated
SOF12 + PR12	\$160,816	10.009	\$40,676	1.351	\$30,115	ext. dominated
SIM12 + SOF12	\$193,471	10.212	\$73,332	1.553	\$47,208	dominated
SOF24 + RBV24	\$214,699	9.636	\$94,559	0.978	\$96,723	dominated

Appendix to: Wong WWL, Lee KM, Singh S, et al. Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. *CMAJ Open* 2017. DOI:10.9778/cmajo.20160161. Copyright © 2017 The Author(s) or their employer(s).
To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.

Genotype 1: Treatment-Experienced Non-cirrhotic Patients

Treatment	Total Cost	Total QALYs	Versus PR Alone			Sequential ICUR
			Incremental Cost	Incremental QALYs	ICUR	
no treatment	\$104,668	9.596	-	-	-	-
PR48	\$118,321	10.282	-	-	-	ext. dominated
PAR/RIT12 + OMB12 + DAS12	\$142,917	11.868	\$24,597	1.586	\$15,506	\$16,836
PAR/RIT12 + OMB12 + DAS12 + RBV12	\$145,743	11.898	\$27,422	1.616	\$16,965	\$93,872
Other Dominated or Extendedly Dominated Treatments						
SIM12 PR24-48 RGT	\$138,660	11.169	\$20,339	0.887	\$22,918	ext. dominated
T12 PR48 q8	\$142,464	11.394	\$24,143	1.113	\$21,702	ext. dominated
B32 PR36-48 RGT	\$143,264	11.122	\$24,943	0.841	\$29,675	dominated
SIM12 PR48	\$143,840	11.406	\$25,519	1.124	\$22,702	dominated
SOF12 + PR12	\$150,153	11.471	\$31,833	1.189	\$26,770	dominated
SOF12 + LDV12	\$154,321	11.761	\$36,001	1.480	\$24,329	dominated
SIM12 + SOF12 +RBV12	\$186,875	11.046	\$68,554	0.765	\$89,659	dominated
SIM12 + SOF12	\$189,079	10.280	\$70,758	-0.001	abs. dominated	dominated

Genotype 1: Treatment-Experienced Cirrhotic Patients

Treatment	Total Cost	Total QALYs	Versus PR Alone			Sequential ICUR
			Incremental Cost	Incremental QALYs	ICUR	
no treatment	\$101,355	7.043	-	-	-	-
PR48	\$119,828	7.924	-	-	-	ext. dominated
SIM12 PR24-48 RGT	\$148,780	9.326	\$28,953	1.402	\$20,655	\$20,774
SOF12 + LDV12 + RBV12	\$172,976	9.933	\$53,148	2.009	\$26,456	\$39,845
SIM12 + SOF12	\$193,052	9.966	\$73,225	2.041	\$35,870	\$618,881
Dominated or Extendedly Dominated Treatments						
B32 PR36-48 RGT	\$153,492	8.758	\$33,664	0.834	\$40,357	dominated
T12 PR48 q8	\$153,691	9.046	\$33,863	1.122	\$30,190	dominated
SIM12 PR48	\$154,912	8.879	\$35,084	0.954	\$36,757	dominated
SOF 12 + PR12	\$162,499	8.941	\$42,671	1.017	\$41,954	dominated
SOF24 + LDV24	\$234,378	9.887	\$114,550	1.962	\$58,371	dominated

Genotype 2: Treatment-Naive Non-cirrhotic Patients

Treatment	Total Cost	Total QALYs	Versus PR Alone			Sequential ICUR
			Incremental Cost	Incremental QALYs	ICUR	
PR24	\$99,904	11.532	-	-	-	-
SOF12 + RBV12	\$143,955	11.749	\$44,051	0.217	\$203,282	\$203,282
Dominated treatments						
no treatment	\$104,904	9.734	\$5,000	-1.798	dominated	dominated
SOF12 + PR12	\$145,731	11.698	\$45,827	0.166	\$276,103	dominated

Genotype 2: Treatment-Naive cirrhotic Patients

Treatment	Total Cost	Total QALYs	Versus PR Alone			Sequential ICUR
			Incremental Cost	Incremental QALYs	ICUR	
no treatment	\$101,355	7.043	-	-	-	-
PR24	\$112,767	9.384	-	-	-	\$4,876
SOF12 + RBV12	\$159,541	10.181	\$46,773	0.797	\$58,659	\$58,659

Genotype 2: Treatment-Experienced Non-cirrhotic Patients

Treatment	Total Cost	Total QALYs	Versus No Treatment			Sequential ICUR
			Incremental Cost	Incremental QALYs	ICUR	
no treatment	\$104,668	9.596	-	-	-	-
SOF12 + RBV12	\$144,023	11.753	\$39,355	2.157	\$18,247	\$18,247
Dominated Treatments						
SOF12 + PR12	\$145,460	11.689	\$40,791	2.092	\$19,494	dominated

Genotype 2: Treatment-Experienced Cirrhotic Patients

Treatment	Total Cost	Total QALYs	Versus No Treatment			Sequential ICUR
			Incremental Cost	Incremental QALYs	ICUR	
no treatment	\$101,355	7.043	-	-	-	-
SOF12 + PR12	\$160,863	10.308	\$59,508	3.265	\$18,226	\$18,226
Dominated or Extendedly Dominated Treatments						
SOF12 + RBV12	\$159,347	9.761	\$57,992	2.718	\$21,338	ext. dominated
SOF16 + RBV16	\$177,502	9.896	\$76,147	2.853	\$26,694	dominated

Genotype 3: Treatment-Naive Non-cirrhotic Patients

Treatment	Total Cost	Total QALYs	Versus PR Alone			Sequential ICUR
			Incremental Cost	Incremental QALYs	ICUR	
no treatment	\$104,183	9.314	-	-	-	-
PR48	\$110,387	11.156	-	-	-	\$3,367
DCV12 + SOF12	\$175,987	11.832	\$65,600	0.675	\$97,158	\$97,158
Dominated or Extendedly Dominated Treatments						
SOF24 + RBV24	\$199,738	11.734	\$89,351	0.578	\$154,599	dominated

Genotype 3: Treatment-Naive cirrhotic Patients

Treatment	Total Cost	Total QALYs	Versus PR Alone			Sequential ICUR
			Incremental Cost	Incremental QALYs	ICUR	
no treatment	\$101,355	7.043	-	-	-	-
PR48	\$120,843	9.335	-	-	-	\$8,504
SOF24 + RBV24	\$215,437	10.362	\$94,594	1.027	\$92,117	\$92,117

Genotype 3: Treatment-Experienced Non-cirrhotic Patients

Treatment	Total Cost	Total QALYs	Versus No Treatment			Sequential ICUR
			Incremental Cost	Incremental QALYs	ICUR	
no treatment	\$103,932	9.167	-	-	-	-
PR48	\$112,301	10.879	\$8,368	1.712	\$4,888	\$4,888
SOF12 + PR12	\$149,249	11.510	\$45,316	2.343	\$19,339	\$58,535
DCV12 + SOF12	\$177,476	11.780	\$73,544	2.612	\$28,151	\$104,857
Dominated or Extendedly Dominated Treatments						
SOF24 + RBV24	\$200,324	11.637	\$96,392	2.470	\$39,025	dominated

Genotype 3: Treatment- Experienced cirrhotic Patients

Treatment	Total Cost	Total QALYs	Versus No Treatment			Sequential ICUR
			Incremental Cost	Incremental QALYs	ICUR	
no treatment	\$101,355	7.043				-
PR48	\$120,880	8.936	\$19,525	1.893	\$10,317	\$10,317
SOF12 + PR12	\$163,647	10.082	\$62,292	3.039	\$20,496	\$37,319
SOF24 + RBV24	\$214,706	9.661	\$113,351	2.618	\$43,292	Dominated

Genotype 4: Treatment-Naive Non-cirrhotic Patients

Treatment	Total Cost	Total QALYs	Versus PR alone			Sequential ICUR
			Incremental Cost	Incremental QALYs	ICUR	
Genotype 4 Treatment-Naive Non-cirrhotic						
no treatment	\$104,904	9.734	-	-	-	-
PR48	\$111,493	11.158	-	-	-	\$4,627
SOF12 + PR12	\$145,731	11.698	\$34,239	0.540	\$63,421	\$63,421
Dominated or Extendedly Dominated Treatments						
SOF24 + RBV24	\$201,602	11.543	\$90,110	0.385	\$234,310	dominated

Genotype 4: Treatment-Naive Cirrhotic Patients

Treatment	Total Cost	Total QALYs	Versus PR Alone			Sequential ICUR
			Incremental Cost	Incremental QALYs	ICUR	
no treatment	\$101,355	7.043	-	-	-	-
PR48	\$120,087	8.608	-	-	-	\$11,970
SOF24 + RBV24	\$215,281	10.208	\$95,194	1.600	\$59,492	\$59,492


Genotype 4: Treatment-Experienced Non-cirrhotic Patients

Treatment	Total Cost	Total QALYs	Versus No Treatment		
			Incremental Cost	Incremental QALYs	ICUR
no treatment	\$104,668	9.596	-	-	-
SOF24 + RBV24	\$201,763	11.503	\$97,095	1.907	\$50,913


Genotype 4: Treatment-Experienced: Cirrhotic Patients

Treatment	Total Cost	Total QALYs	Versus No Treatment		
			Incremental Cost	Incremental QALYs	ICUR
no treatment	\$101,355	7.043	-	-	-
SOF24 + RBV24	\$215,142	10.093	\$113,787	3.050	\$37,303


Appendix Figure A1: Result of Sensitivity Analyses: Tornado Diagrams




G1 Treatment Experienced Non-cirrhotic




G1 Treatment Experienced Cirrhotic




G2 Treatment Naïve Non-cirrhotic




G2 Treatment Naïve Cirrhotic




G2 Treatment Experienced Non-cirrhotic




G2 Treatment Experienced Cirrhotic




G3 Treatment Naïve Non-cirrhotic




G3 Treatment Naïve Cirrhotic




G3 Treatment Experienced Non-cirrhotic




G3 Treatment Experienced Cirrhotic




G4 Treatment Naïve Non-cirrhotic




G4 Treatment Naïve Cirrhotic



G4 Treatment Experienced Non-cirrhotic




G4 Treatment Experienced Cirrhotic




Appendix Figure A2: Result of Sensitivity Analyses: Acceptability Curve


G1 Treatment Naïve Non-cirrhotic




G1 Treatment Naïve Cirrhotic




G1 Treatment Experienced Non-cirrhotic




G1 Treatment Experienced Cirrhotic




G2 Treatment Naïve Non-cirrhotic




G2 Treatment Naïve Cirrhotic




G2 Treatment Experienced Non-cirrhotic




G2 Treatment Experienced Cirrhotic




G3 Treatment Naïve Non-cirrhotic




G3 Treatment Naïve Cirrhotic




G3 Treatment Experienced Non-cirrhotic




G3 Treatment Experienced Cirrhotic




G4 Treatment Naïve Non-cirrhotic



G4 Treatment Naïve Cirrhotic



G4 Treatment Experienced Non-cirrhotic



G4 Treatment Experienced Cirrhotic

